Annovis to Host Corporate Update Webinar on January 28, 2026
Annovis (NYSE: ANVS) will host a corporate update webinar on January 28, 2026 at 4:30 p.m. ET featuring President and CEO Maria Maccecchini, Ph.D..
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Annovis (NYSE: ANVS) will host a corporate update webinar on January 28, 2026 at 4:30 p.m. ET featuring President and CEO Maria Maccecchini, Ph.D.. The presentation will review the company’s recent progress, ongoing late‑stage clinical programs in Alzheimer’s and Parkinson’s disease, strategic direction, and upcoming early‑2026 milestones, followed by a live Q&A.
The webinar is open to shareholders, patients, investigators, and other interested parties; participants are encouraged to register via the company registration link and may submit questions in advance to ir@annovisbio.com.
Details
News Market Reaction – ANVS
On Dec 16, the day this news came out, ANVS closed 3.97% above the previous close.
Data tracked by StockTitan Argus for the Dec 16 session.
Key Figures
- Webinar date
- January 28, 2026
- Scheduled corporate update webinar
- Webinar time
- 4:30 p.m. ET
- Scheduled corporate update webinar
Historical Context
-
Phase 3 Parkinson’s biomarker data presented at Parkinson Study Group meeting.
-
Two CTAD 2025 presentations on buntanetap cognition and Phase 3 AD design.
-
FDA Type C meeting scheduled for PDD and reaffirmed alignment on Phase 3 AD.
-
Phase 3 data showing halted cognitive decline and tau biomarker reductions.
-
Q3 2025 financials plus Phase 3 AD progress and new buntanetap PK data.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
Alzheimer's disease medical
Parkinson's disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.
The webinar will feature Maria Maccecchini, Ph.D., President and CEO, who will provide an overview of the Company’s recent progress, ongoing clinical programs, and strategic directions.
Webinar details
- Date: Wednesday, January 28, 2026
- Time: 4:30 p.m. ET
- Presenter: Maria Maccecchini, Ph.D., President and CEO
- Registration link
“We look forward to beginning the year by sharing a comprehensive update on Annovis with everyone who has been following our journey,” said Maria Maccecchini, Ph.D., President and CEO. “The Company has witnessed strong momentum driven by clinical progress and corporate achievements, with additional milestones expected in early 2026. During this webinar, we will share where we are today, outline our path forward, and engage in direct dialogue with the community.”
The webinar is open to shareholders, patients, investigators, and other interested parties. Participants are encouraged to submit questions in advance by emailing ir@annovisbio.com.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.